Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Our passive immunity patent portfolio concerns the local or topical administration of monoclonal or polyclonal antibody compositions in the prevention and treatment of infectious disease. More
This TACE inhibitory protein could be used as a new therapeutic agent against chronic inflammatory diseases that are mediated by TNF-alpha. More
Academics at the University of Nottingham have invented a new method to inactivate viruses without affecting valuable blood and plasma proteins. More
Multidrug-resistant Pseudomonas antibiotic with robust in vivo efficacy and novel target (undisclosed) More
Compositions and methods for improving the growth characteristics of cells engineered to produce biologically active products such as antibodies or glycosylated proteins. More
The inactivation approach presented in this technology provides for a safe, non-infectious composition for vaccination against the corresponding agent. More
Adjuvant that induces a potent antigen-specific CD8 cytotoxic T-cell response with long lasting immunity More
Third generation long-acting, site-specific PEGylated interferon-alpha, having one predominate positional isomer, offering a longer half-life and so requiring a less frequent dosage regime. The new design also gives improved production yields. More
Pharmaceutical composition based on Mutants created by insertions and deletions of Ezrin More
An in vitro hepatitis C virus (HCV) replication system that is capable of producing viral particles in a culture medium More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Bacteria or virus
- Bioterrorism
- Diseases
- Hepatitis (other)
- Nosocomial infections
- Parasitic diseases
- Treatments
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us